IDF Diabetes Atlas. 8th edition, 2017. http://www.diabetesatlas.org/resources/2017-atlas.html.http://www.diabetesatlas.org/resources/2017-atlas.html
IDF Diabetes Atlas. 8th edition, 2017. http://www.diabetesatlas.org/resources/2017-atlas.html.http://www.diabetesatlas.org/resources/2017-atlas.html
Koivusalo SB, Rono K, Klemetti MM, Roine RP, Lindstrom J, Erkkola M, et al. Gestational diabetes mellitus can be prevented by lifestyle intervention: the Finnish Gestational Diabetes Prevention Study (RADIEL): a randomized controlled trial. Diabetes Care, 2016, 39(1): 24–30.
Magliano DJ, Soderberg S, Zimmet PZ, Chen L, Joonas N, Kowlessur S, et al. Explaining the increase of diabetes prevalence and plasma glucose in Mauritius. Diabetes Care, 2012, 35(1): 87–91.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract, 2010, 87(1): 4–14.
Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет, 2017, 20(1): 13-41.
Sinnreich M, Taylor BV, Dyck PJ. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist, 2005, 11: 63–79.
Smith AG, Singleton JR. Diabetic neuropathy. Continuum, 2012, 18: 60–84.
Tracy JA, Engelstad JK, Dyck PJ. Microvasculitis in diabetic lumbosacral radiculoplexus neuropathy. J Clin Neuromuscul Dis, 2009, 11: 44–48.
Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents. Diab Vasc Dis Res, 2006, 3(3): 147–158.
Мкртумян А.М., Подачина С.В., Доскина Е.В., Аблина К.Н. Эффективное лечение диабетической нейропатии комплексным препаратом Кокарнит. Эффективная фармакотерапия. Эндокринология, 2015, 5(43): 34-39.
Балаболкин М.И. Диабетология. М., 2000. 672 с/ Balabolkin MI. Diabetology. M., 2000. 672 p.
Pop-Busui R, Boulton AJ, Feldman EL et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, Jan, 40(1): 136-154.
Strom A, Kaul K, Brüggemann J, et al. Lower serum extracellular superoxide dismutase levels are associated with polyneuropathy in recentonset diabetes. ExpMolMed, 2017, Nov 17, 49(11): e394.
Bouhassira D, Attal N, Alchaar H, Boureau F et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain, 2005, 114(1–2): 29–36.
Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J, 2006, 82: 95–100.
Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care, 2010, 33: 2285–2293.
Zochodne DW. Diabetic neuropathies: features and mechanisms. Brain Pathol, 1999, 9: 369–391.
Zochodne DW. Diabetes mellitus and the peripheral nervous system: Manifestations and mechanisms. Muscle and Nerve, 2007, 36: 144–166.
Zochodne DW. Diabetic polyneuropathy: an update. Curr Opin Neurol, 2008, 21: 527–533.
Dyck PJ, Albers JW, Andersen H, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev, 2011, 27: 620–628.
Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology, 1993, 43: 817–824.
Dyck PJ, Dyck PJB. Diabetic polyneuropathy: section III. In: Diabetic Neuropathy. 2nd ed. PJ Dyck, PK Thomas (eds). Philadelphia: W.B. Saunders, 1999: 255–78.
Dyck PJ. Severity and staging of diabetic polyneuropathy. In: Textbook of Diabetic Neuropathy. FA Gries, NE Cameron, PA Low, D Ziegler (eds). Stuttgart: Thieme, 200: 170–5.
International Diabetes Federation. Clinical Practice Recommendation on the Diabetic Foot: A guide for health care professionals: International Diabetes Federation, 2017.
Reed LJ, De Busk BG, Gunsalus IC, Hornberger CS. Cristalline alpha-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Science, 1951, 114: 93–94.
Suzuki Y. et. al. Lipoate prevents glucose-induced protein modifications. Free Radic Res Common, 1992, 17: 211-217.
Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother, 2014, 15(18): 2721-31.
Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer, 2014, 22(5): 1223-31.
Battisti E, Albanese A, Guerra L, Argnani L, Giordano N. Alpha lipoic acid and superoxide dismutase in the treatment of chronic low back pain. Eur J Phys Rehabil Med, 2013, 49(5): 659-64.
Rochette L, Ghibu S, Richard C, Zeller M, et al. Direct and indirect antioxidant properties of α-lipoic acid and therapeutic potential. Mol Nutr Food Res, 2013, 57(1): 114-125.
Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes, 2000, 49(6): 1006–1015.
Ford I, Cotter MA, Cameron NE, Greaves M. The effects of treatment with alpha-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Metabolism, 2001, 50(8): 868–875.
Heitzer T, Finckh B, Albers S. Benefficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med, 2001, 31: 53–61.
Ziegler D, Low PA, Litchy WJ et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care, 2011, 34(9): 2054–2060.
Han T, Bai J, Liu W, Hu Y. A systematic review and metaanalysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol, 2012, 167(4): 465–471.
https://www.rlsnet.ru/tn_index_id_3800.htm.https://www.rlsnet.ru/tn_index_id_3800.htm
https://www.rlsnet.ru/tn_index_id_3800.htm.https://www.rlsnet.ru/tn_index_id_3800.htm
Недосугова Л.В. Альфа-липоевая кислота (Эспа-липон) в комплексном лечении диабетической нейропатии. Международный эндокринологический журнал, 2007, 8(2): 49–51.
Клиническое исследование Espalipon II. Дозировка 600 мг (№ исследования 616-14-94002 02.05.1995.
Benbow SJ, MacFarlane IA. Painful diabetic neuropathy. Baillieres Best Pract Res Clin Endocrinol Metab, 1999, 13(2): 295-308.
Backonja M. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain, 2000, 16(2 Suppl.): 67-72.
Chou R, Carson S, Chan BK: Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med, 2009, 24: 178-188.
Kempler P, Amarenco G, Freeman R, Frontoni S, Horowitz M, Stevens M, Low P, Pop-Busui R, Tahrani A, Tesfaye S, Várkonyi T, Ziegler D, Valensi P, Toronto Consensus Panel on Diabetic Neuropathy: Gastrointestinal autonomic neuropathy, erectile-, bladder- and sudomotor dysfunction in patients with diabetes mellitus: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev, 2011.
Williams G., Pickup C. Handbook of diabetes. London, 1996.